Drug intelligence / Profile preview

ODC-αCD28

Development stage: Unknown
Lead developer: Trutino Biosciences
Modality: Recombinant Proteins and Enzymes

Overview

ODC-αCD28 is an experimental biologic drug candidate designed to modulate immune responses by targeting the CD28 receptor, a key costimulatory molecule on T cells. The drug likely functions as an agonist or modulator of CD28, aiming to enhance or regulate T cell activation for therapeutic purposes. Specific details about its mechanism, clinical indications, and development status are limited in public sources as of June 2025.

Targets

CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on ODC-αCD28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ODC-αCD28.

Explore the full profile